Evogene Ltd. (EVGN)
Total Valuation
Evogene has a market cap or net worth of $32.52 million. The enterprise value is $7.43 million.
| Market Cap | 32.52M |
| Enterprise Value | 7.43M |
Important Dates
The last earnings date was Wednesday, November 15, 2023, before market open.
| Earnings Date | Nov 15, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
Evogene has 50.55 million shares outstanding.
| Shares Outstanding | 50.55M |
| Owned by Insiders (%) | 2.04% |
| Owned by Institutions (%) | 2.71% |
| Float | 46.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.70 |
| Forward PS | 1.34 |
| PB Ratio | 1.76 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.26, with a Debt / Equity ratio of 0.65.
| Current Ratio | 6.26 |
| Quick Ratio | 6.25 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.94 |
Financial Efficiency
Return on equity (ROE) is -97.90% and return on invested capital (ROIC) is -74.21%.
| Return on Equity (ROE) | -97.90% |
| Return on Assets (ROA) | -37.40% |
| Return on Capital (ROIC) | -74.21% |
| Revenue Per Employee | $41,766 |
| Profits Per Employee | -$148,000 |
| Employee Count | 137 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 11.93 |
Taxes
In the past 12 months, Evogene has paid $16,000 in taxes.
| Income Tax | 16,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.03% in the last 52 weeks. The beta is 1.03, so Evogene's price volatility has been similar to the market average.
| Beta (1Y) | 1.03 |
| 52-Week Price Change | +6.03% |
| 50-Day Moving Average | 0.57 |
| 200-Day Moving Average | 0.72 |
| Relative Strength Index (RSI) | 60.70 |
| Average Volume (30 Days) | 115,114 |
Short Selling Information
| Short Interest | 217,497 |
| Short Previous Month | 180,362 |
| Short % of Shares Out | 0.44% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.18 |
Income Statement
In the last 12 months, Evogene had revenue of $5.72 million and -$20.28 million in losses. Loss per share was -$0.48.
| Revenue | 5.72M |
| Gross Profit | 4.06M |
| Operating Income | -22.66M |
| Pretax Income | -20.26M |
| Net Income | -20.28M |
| EBITDA | -16.95M |
| EBIT | -19.54M |
| Loss Per Share | -$0.48 |
Balance Sheet
The company has $37.23 million in cash and $12.03 million in debt, giving a net cash position of $25.20 million or $0.50 per share.
| Cash & Cash Equivalents | 37.23M |
| Total Debt | 12.03M |
| Net Cash | 25.20M |
| Net Cash Per Share | $0.50 |
| Equity / Book Value | 18.51M |
| Book Value Per Share | 0.37 |
| Working Capital | 34.07M |
Cash Flow
In the last 12 months, operating cash flow was -$17.91 million and capital expenditures -$872,000, giving a free cash flow of -$18.78 million.
| Operating Cash Flow | -17.91M |
| Capital Expenditures | -872,000 |
| Free Cash Flow | -18.78M |
| FCF Per Share | -$0.38 |
Margins
Gross margin is 71.02%, with operating and profit margins of -396.05% and -354.35%.
| Gross Margin | 71.02% |
| Operating Margin | -396.05% |
| Pretax Margin | -354.07% |
| Profit Margin | -354.35% |
| EBITDA Margin | -296.14% |
| EBIT Margin | -341.40% |
| FCF Margin | -328.22% |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -62.13% |
| FCF Yield | -57.55% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.70% |
| Shareholder Yield | -18.70% |
Analyst Forecast
The average price target for Evogene is $3.62, which is 462.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.62 |
| Price Target Difference | 462.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 19, 2013. It was a reverse split with a ratio of 1:2.
| Last Split Date | Nov 19, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:2 |
Scores
Evogene has an Altman Z-Score of -5.5 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.5 |
| Piotroski F-Score | 3 |